The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations

Wednesday, September 05, 2012

Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations08:30 EDT Wednesday, September 05, 2012NEW YORK, Sept. 5, 2012 /PRNewswire/ --  Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:STIFEL NICOLAUS 2012 HEALTHCARE CONFERENCE- Presentation Date:  Thursday, September 6, 2012- Presentation Time:  1:30pm ETRODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE- Presentation Date:  Monday, September 10, 2012- Presentation Time:  3:40pm  ET2012 UBS GLOBAL LIFE SCIENCES CONFERENCE- Presentation Date:  Thursday, September 20, 2012- Presentation Time:  11:00am ETEach of these presentations will be live audio webcast and accessible from the Investor Information page of the Company's Website at An archived version of each webcast will be available following the conclusion of the live presentation.About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City. KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.comSOURCE Keryx Biopharmaceuticals, Inc.